DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
A•••••• A•••••••• G•••• P•• L••
Pharmaceuticals, Biotechnology & Life Sciencesgroup grade Aoff every schedule since Sep 30, 2025sponsor unattributed
Also written as: 0; Biotechnology & Life Sciences; Pharmaceuticals
Nothing material in the last 200 days. Last change: 30 Sep 2025, $10.8M principal held by 1 lender; matures Jun 2028.
Mark path, consensus per quarter end
100¢ · 94¢ · 93¢ · 99¢ · 100¢Q3 2024 to Q3 2025
Principal held
at least $10.8M
sum of BDC pieces, a lower bound
Fair value
$7.1M
100c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
2
0 equity pieces beside them
Next maturity
Jun 1, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2021
latest Sep 30, 2025
Events
7
dated, non-routine
Lender marks
each lender's own fair value over cost at Sep 30, 2025, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| F• K•• C•••••• C••• | $10.8M | 100¢ | +1 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| F• K•• C•••••• C••• | unstated lien unstated | $10.8M | $7.1M 100c | S+600 bp |
Capital structure as the BDCs see it
latest quarter end Sep 30, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Jun 30, 2023 | at least $56.5M | 100c | S+675 bp | Jun 5, 2028 | 1 |
| other lien unstated exited Sep 30, 2025 | at least $10.8M | 100c | S+600 bp | Jun 1, 2028 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2025 | 1 | $10.8M | $7.1M | 100c | 0 |
| Jun 30, 2025 | 1 | $10.8M | $7.0M | 99c | 0 |
| Mar 31, 2025 | 1 | $10.8M | $6.6M | 93c | 0 |
| Dec 31, 2024 | 1 | $21.6M | $13.4M | 94c | 0 |
All 10 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2024 | 1 | $10.8M | $7.1M | 100c | 0 |
| Jun 30, 2023 | 1 | $56.5M | $36.2M | 100c | 0 |
| Mar 31, 2023 | 1 | $45.7M | $30.6M | 91c | 0 |
| Dec 31, 2022 | 1 | $91.4M | $62.2M | 93c | 0 |
| Sep 30, 2022 | 1 | $45.7M | $29.4M | 89c | 0 |
| Dec 31, 2021 | 1 | $45.7M | $33.2M | 102c | 0 |
What changed
- Facility left every BDC scheduleSep 30, 2025
- Marked down (one lender)Dec 31, 2024
- Spread changed (observed)Jun 30, 2023
- Facility left every BDC scheduleJun 30, 2023
- Mark recoveredJun 30, 2023
Full timeline · 11 eventsShow fewer
- Maturity extended (observed)Jun 30, 2023
- Spread increasedJun 30, 2023
- Maturity extended (observed)Jun 30, 2023
- Marked down across lendersSep 30, 2022
- Marked down (one lender)Sep 30, 2022
- New borrower on a BDC scheduleDec 31, 2021
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- ARROTEX AUSTRALIAderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticals, Biotechnology & Life Sciencesreportedas one filer wrote it